home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

argenx SE - American Depositary Shares (NQ:ARGX)

802.13 +4.37 (+0.55%)

Streaming Delayed Price Updated: 11:45 AM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about argenx SE - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy ↗

April 10, 2024

Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current...

Via Benzinga

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

March 27, 2024

From argenx SE

Via GlobeNewswire

argenx Announces Annual General Meeting of Shareholders on May 7, 2024

March 26, 2024

From argenx SE

Via GlobeNewswire

Key Takeaways From argenx Analyst Ratings ↗

March 26, 2024

Via Benzinga

Tesla To $120? Here Are 10 Top Analyst Forecasts For Tuesday ↗

March 26, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Earnings Scheduled For February 29, 2024 ↗

February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Via Benzinga

argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia

March 26, 2024

From argenx SE

Via GlobeNewswire

Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 21, 2024

Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance.

Via Benzinga

Guess? Posts Upbeat Earnings, Joins Lufax, Nortech Systems And Other Big Stocks Moving Higher On Thursday ↗

March 21, 2024

U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Thursday.

Via Benzinga

Topics Stocks

Why Is European Pharma Giant Argenx Valued At Over $20B Trading Higher On Thursday? ↗

March 21, 2024

Argenx shares rise on Chugai's gMG trial disappointment. FDA-approved Vyvgart for anti-acetylcholine receptor antibody-positive adult patients. Enspryng's Phase 3 study results disappoint. Vyvgart...

Via Benzinga

Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results ↗

March 21, 2024

Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 21, 2024

Via Benzinga

Why Micron Therapies Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket ↗

March 21, 2024

Shares of Micron Technology, Inc. (NASDAQ: MU) rose sharply in today’s pre-market trading as the company reported upbeat results for its second quarter and issued

Via Benzinga

argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting

March 07, 2024

From argenx SE

Via GlobeNewswire

argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

February 29, 2024

From argenx SE

Via GlobeNewswire

argenx to Present at Upcoming Investor Conferences

February 26, 2024

From argenx SE

Via GlobeNewswire

argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024

February 22, 2024

From argenx SE

Via GlobeNewswire

3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition ↗

February 21, 2024

Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.

Via InvestorPlace

argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy

February 20, 2024

From argenx SE

Via GlobeNewswire

5 medical stocks growing earnings by triple digits

February 06, 2024

There is a little known way to pick stocks like the pros do, and today's exercise points you to five high-probability winners in a sector that's quickly turning

Via MarketBeat

Topics Economy

New Hope For Patients With Chronic Autoimmune Conditions: Johnson & Johnson's Investigational Drug Meets Primary Goal In Two Studies ↗

February 05, 2024

Johnson & Johnson's nipocalimab shows promise in Phase 3 VIVACITY for gMG & Phase 2 DAHLIAS for SjD. FDA-approved Vyvgart Hytrulo for gMG.

Via Benzinga

Halozyme's Ambitious Five-Year Plan: Analysts Optimistic On Growth, Eyeing Market Expansion ↗

January 18, 2024

Explore Halozyme Therapeutics' promising financial outlook up to 2028. Discover revenue forecasts, earnings projections, and market insights.

Via Benzinga

argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis

January 18, 2024

From argenx SE

Via GlobeNewswire

5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond ↗

January 15, 2024

These five biotech companies could have a lot of room to run.

Via The Motley Fool

argenx Highlights 2024 Strategic Priorities

January 08, 2024

From argenx SE

Via GlobeNewswire

argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference

January 02, 2024

From argenx SE

Via GlobeNewswire

Stock Market Rally Is In Merry Mood Heading Into Christmas Weekend: Weekly Review ↗

December 22, 2023

Despite a Wednesday tumble, the major indexes are right at 2023 highs.

Via Investor's Business Daily

Argenx's Autoimmune Trial Stumble: Analysts Cut Price Targets, Warn of Risky Outcomes ↗

December 21, 2023

Wednesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADDRESS Phase 3 study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with pemphigus...

Via Benzinga

Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off ↗

December 21, 2023

Immunovant reversed its fortunes Thursday following an Argenx-tied selloff Wednesday.

Via Investor's Business Daily

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

December 21, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com